Immunotherapy for non-clear cell kidney cancer

The following interview with Dr Eric Jonasch, medical oncologist from MD Anderson Cancer Centre in Texas, USA, discusses various clinical trials of immunotherapy for the treatment of rare subtypes of kidney cancer, such as papillary and chromophobe renal cell carcinoma (RCC). Dr Jonasch was interviewed at the 2018 American Society of Clinical Oncology (ASCO) annual […]

read more

Recommendations for the management of rare kidney cancers

Patients diagnosed with a rare kidney cancer are often treated the same way as clear-cell renal cell carcinoma (ccRCC) patients, despite little evidence from randomised trials. Identifying the subtype of kidney cancer by looking at the genetic make-up of tumour cells to group patients by rare kidney cancer subtype may improve outcomes. Availability of potential […]

read more

Sunitinib vs everolimus for advanced non-clear cell kidney cancer

In a recent study published in the journal Lancet Oncology, researchers compared everolimus versus sunitinib in 108 patients with metastatic papillary, chromophobe, or unclassified non–clear-cell renal cell carcinoma (RCC) in a phase 2 randomised, industry-sponsored clinical trial. Nearly two thirds of the patients had papillary histology. Progression-free survival was longer with sunitinib in patients with […]

read more
Showing 11 to 13 of 13 results